[68ga]ga dota-5g
Small moleculeexperimentalImaging agent
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 18, 2020 (NCT04665947)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07020806 | Phase 1 | Jun 30, 2025 | University of California, Davis |
| NCT06389123 | Phase 1 | Apr 1, 2024 | National Institutes of Health (NIH), University of California, Davis |
| NCT06228482 | Phase 1 | Jan 22, 2024 | Department of Defense, University of California, Davis |
| NCT04665947 | Early Phase 1 (Phase 1) | Dec 18, 2020 | University of California, Davis |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of California, Davis | Academic/Hospital | 4 | 4 | 1 | 2020 |
| Department of Defense | Government | 1 | 0 | 1 | 2024 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1